临床胸主动脉瘤中膜1型基质金属蛋白酶活性与细胞内定位的调控
研究比较小(<5 cm,n=8)与大(>6.5 cm,n=8)胸主动脉瘤(TAA)患者及正常对照(n=8)主动脉组织中MT1-MMP、MMP-2及PKC-δ水平,并在小鼠主动脉成纤维细胞中评估PKC介导磷酸化对MT1-MMP定位与功能的影响。结果显示MT1-MMP磷酸化通过改变细胞定位使其功能从激活MMP-2转向细胞内信号传导。
要点
- 两TAA组MT1-MMP丰度均高于对照,但活性MMP-2仅在大TAA组升高。
- 小TAA组磷酸化MT1-MMP与活化PKC-δ丰度高于大TAA组。
- PKC激活剂PMA诱导MT1-MMP内化、增强phospho-Smad2并减少MMP-2活化。
核心结论
- MT1-MMP的磷酸化通过决定其细胞定位来调控活性,使其作用从激活MMP-2转向细胞内信号传导。
- 靶向抑制MT1-MMP可能成为减缓TAA发展的治疗方向。
研究设计与样本
- 研究检测小TAA(<5 cm,n=8)、大TAA(>6.5 cm,n=8)患者及正常对照(n=8)主动脉组织中MMP-2、天然与磷酸化MT1-MMP及PKC-δ水平。
- 在对照与4周TAA小鼠分离的主动脉成纤维细胞中评估GFP标记MT1-MMP的细胞定位。
- 用PKC激活剂PMA(100 nM)联合或不联合PKC-δ特异性抑制剂röttlerin(3 μM)处理,评估磷酸化对MT1-MMP定位与功能的影响。
主要发现
- 与对照相比,两TAA组主动脉MT1-MMP丰度均增加。
- 活性MMP-2仅在大TAA组增加。
- 小TAA组磷酸化MT1-MMP与活化PKC-δ丰度高于大TAA组。
- MT1-MMP在对照小鼠主动脉成纤维细胞定位于质膜,在TAA小鼠中定位于内体。
- PMA处理诱导MT1-MMP-GFP内化、增强phospho-Smad2并减少MMP-2活化,röttlerin预处理可抑制这些效应。
临床怎么用
- 临床解读TAA组织中MT1-MMP总丰度时需结合其磷酸化状态与细胞内定位,而非仅看总量。
- PKC-δ介导的MT1-MMP磷酸化可能作为区分TAA进展阶段的分子线索。
局限性
- 人类主动脉组织各组样本量均为8例,结果需更大样本验证。
- 细胞定位与功能调控实验在小鼠主动脉成纤维细胞中进行,向人临床转化需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Membrane type-1 matrix metalloproteinase (MT1-MMP) is elevated during thoracic aortic aneurysm (TAA) development in mouse models, and plays an important role in the activation of matrix metalloproteinase (MMP)-2 and the release of matrix- bound transforming growth factor-β. In this study, we tested the hypothesis that MT1-MMP is subject to protein kinase C (PKC)-mediated regulation, which alters intracellular trafficking and activity with TAAs. METHODS: Levels of MMP-2, native and phosphorylated MT1-MMP, and PKC-δ were measured in aortic tissue from patients with small TAAs (<5 cm; n = 8) and large TAAs (>6.5 cm; n = 8), and compared with values measured in normal controls (n = 8). Cellular localization of green fluorescent protein (GFP)-tagged MT1-MMP was assessed in aortic fibroblasts isolated from control and 4-week TAA mice. The effects of PKC-mediated phosphorylation on MT1-MMP cellular localization and function (active MMP-2 vs phospo-Smad2 abundance) were assessed after treatment with a PKC activator (phorbol-12-myristate-13-acetate [PMA], 100 nM) with and without a PKC-δ-specific inhibitor (röttlerin, 3 μM). RESULTS: Compared with controls, MT1-MMP abundance was increased in aortas from both TAA groups. Active MMP-2 was increased only in the large TAA group. The abundances of phosphorylated MT1-MMP and activated PKC-δ were enhanced in the small TAA group compared with the large TAA group. MT1-MMP was localized on the plasma membrane in aortic fibroblasts from control mice and in endosomes from TAA mice. Treatment with PMA induced MT1-MMP-GFP internalization, enhanced phospho-Smad2, and reduced MMP-2 activation, whereas röttlerin pretreatment inhibited these effects. CONCLUSIONS: Phosphorylation of MT1-MMP mediates its activity through directing cellular localization, shifting its role from MMP-2 activation to intracellular signaling. Thus, targeted inhibition of MT1-MMP may have therapeutic relevance as an approach to attenuating TAA development.
引用
- Ikonomidis JS, Nadeau EK, Akerman AW, et al. Regulation of membrane type-1 matrix metalloproteinase activity and intracellular localization in clinical thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 2016. PMID: 27923483. doi:10.1016/j.jtcvs.2016.10.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。